Epidemiological Research Catalog
Structural indexing of filovirus literature, molecular vector mechanics, and comparative viral lineage metrics.
1. Taxonomy of the Genus Orthoebolavirus
The genus Orthoebolavirus forms characteristically elongated filamentous structures measuring roughly 80 nm in diameter and up to 14,000 nm in length. To date, six distinct viral lineages have been structurally isolated, varying drastically in human virality and pathogenesis profiles:
The most lethal lineage isolated. Discovered in Yambuku (1976), it features profound viral replication metrics and serves as the primary target for FDA-approved monoclonal therapies.
Isolated concurrently in Nzara (1976). Exhibiting distinct structural variations in viral surface proteins, it bypasses countermeasures optimized for Zaire.
Isolated in Uganda (2007). Exhibits slower intracellular replication kinetic properties. It is highly elusive under conventional immunoassay screenings due to significant glycoprotein divergence.
2. Molecular Entry & Replication
Infection initiates via close direct contact of broken skin or mucosal pathways with fluid vectors. At the cellular border, the viral outer envelope trimeric glycoprotein (GP) attaches to host surface receptors, driving rapid macropinocytosis. Once inside the cellular endosome, the core binds directly with the internal transport receptor protein Niemann-Pick C1 (NPC1), unlocking final envelope fusion.
3. Clinical Progression Matrix
The internal systemic incubation period spans a variable timeline from 2 to 21 days (mean observation curve sits at 8-10 days). Pathogenesis systematically advances from an initial febrile "dry phase" straight to gastrointestinal fluid loss and multi-organ vascular failure during the "wet phase".
4. Historical Transmission Catalog
| Year | Lineage Strain | Primary Geographic Sectors | Confirmed/Suspected Cases | Mortality Rate (CFR) | Status |
|---|---|---|---|---|---|
| 2026 | Bundibugyo ebolavirus | Ituri Province, Bunia, Mongbwalu, Rwampara, Kinshasa, Kampala, Butembo, Nyakunde, Kisangani, Tshopo, Bunia, North Kivu, South Kivu, Democratic Republic of the Congo, Uganda, South Sudan, Republic of the Congo | 1,010 | 23.0% | Active |
| 2018 | Zaire ebolavirus | Kivu region, DRC | 3,470 | 65.9% | Contained |
| 2014 | Zaire ebolavirus | West Africa, Guinea, Liberia, Sierra Leone | 28,616 | 39.5% | Contained |
| 2007 | Bundibugyo ebolavirus | Bundibugyo, Uganda | 149 | 24.8% | Contained |
| 2003 | Zaire ebolavirus | Cuvette-Ouest, Republic of the Congo | 143 | 89.5% | Contained |
| 2000 | Sudan ebolavirus | Gulu, Masindi, Mbarara, Uganda | 425 | 52.7% | Contained |
| 1995 | Zaire ebolavirus | Kikwit, Zaire (now DRC) | 315 | 80.6% | Contained |
| 1976 | Zaire ebolavirus | Yambuku, Zaire (now DRC) | 318 | 88.1% | Contained |
| 1976 | Sudan ebolavirus | Nzara, Maridi, Sudan | 284 | 53.2% | Contained |
5. Institutional Medical Countermeasure Index
| Countermeasure Class | Zaire Lineage Support Status | Bundibugyo Lineage Support Status |
|---|---|---|
| Preventative Immunizations | Approved: FDA licensed single-dose Ervebo (rVSV-ZEBOV). | Experimental: Ervebo yields zero cross-protection. Trials for candidates like ChAdOx-BDBV are ongoing under emergency protocols. |
| Monoclonal Antibody Infusions | Standard of Care: Authorized deployment of Inmazeb and Ebanga. | Unavailable: Existing options exhibit zero neutralization efficacy against the structural envelope mapping of BDBV. |
Strict Medical Disclaimer
Ebola.ai is an automated public health data aggregate and intelligence platform utilizing real-time digital surveillance systems. Content published here is for geopolitical mapping, tracking, and information extraction purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always consult official directives from the World Health Organization (WHO), local Ministries of Health, or your primary healthcare provider for actionable clinical guidelines.